Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer

by Balar, Arjun V , Lopez, Lidia P , Shore, Neal , Galsky, Matthew D , Rosenberg, Jonathan E , Meeks, Joshua J , Grivas, Petros , Campbell, Matthew T , Black, Peter C , Plimack, Elizabeth R , Steinberg, Gary D , Kamat, Ashish M , Dykstra, Gail S , Hoimes, Christoper J , Gupta, Shilpa

in antineoplastic protocols / Biomarkers / Bladder cancer / Cancer / Clinical practice guidelines / FDA approval / Guidelines as Topic / Humans / Immunotherapy / Immunotherapy - methods / Position and Guidelines / Position article and guidelines / Societies, Medical - standards / urinary bladder neoplasms / Urinary Bladder Neoplasms - drug therapy / urologic neoplasms

2021

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer

2021

Confirm

Do you wish to request the book?

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer

2021

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer

Balar, Arjun V,

Lopez, Lidia P,

Shore, Neal,

Galsky, Matthew D,

Rosenberg, Jonathan E,

Meeks, Joshua J,

Grivas, Petros,

Campbell, Matthew T,

Black, Peter C,

Plimack, Elizabeth R,

Steinberg, Gary D,

Kamat, Ashish M,

Dykstra, Gail S,

Hoimes, Christoper J,

Gupta, Shilpa

2021

Overview

A number of immunotherapies have been developed and adopted for the treatment of urothelial cancer (encompassing cancers arising from the bladder, urethra, or renal pelvis). For these immunotherapies to positively impact patient outcomes, optimal selection of agents and treatment scheduling, especially in conjunction with existing treatment paradigms, is paramount. Immunotherapies also warrant specific and unique considerations regarding patient management, emphasizing both the prompt identification and treatment of potential toxicities. In order to address these issues, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in the field of immunotherapy for urothelial cancer. The expert panel developed this clinical practice guideline (CPG) to inform healthcare professionals on important aspects of immunotherapeutic treatment for urothelial cancer, including diagnostic testing, treatment planning, immune-related adverse events (irAEs), and patient quality of life (QOL) considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers treating patients with urothelial cancer.

Share this book

Add to My Shelf

Publisher

BMJ Publishing Group Ltd,BMJ Publishing Group LTD,BMJ Publishing Group

Subject

antineoplastic protocols

/ Biomarkers

/ Bladder cancer

/ Cancer

/ Clinical practice guidelines

/ FDA approval

/ Guidelines as Topic